Humanigen Inc (HGENQ)

[DonDonDonDon]

being peer review published in the Lancet is a major milestone! hugely legitimizing and will pave the way to approvals and major revenue for $HGEN - the market is completely oblivious to the opportunity here at the moment

It is frustrating that the market doesn't respect the peer review news but ultimately it is regulatory agencies that matter. The US FDA and MHRA will respect lenzilumab getting peer reviewed in The Lancet. Government regulatory agencies also understand the importance of lenz being variant agnostic. The currently available armamentarium is ill-equipped to fight the Omicron variant. Lenz has 154% efficacy and will fight Omicron equally well as previous variants. Lenzilumab's time is coming.